Literature DB >> 16699746

Myocardial injury modulates the innate immune system and changes myocardial sensitivity.

Georg Baumgarten1, Se-Chan Kim, Heidi Stapel, Volker Vervölgyi, Anne Bittig, Andreas Hoeft, Rainer Meyer, Christian Grohé, Pascal Knuefermann.   

Abstract

OBJECTIVE: Transverse aortic constriction (TAC) results in a transient increase of proinflammatory cytokines, which return to baseline levels within 3 d. In contrast to cytokine baseline levels, the myocardium remains capable to respond even stronger to a new stimulus. As the molecular mechanisms for this phenomenon are unknown, we tested whether TAC modulates the innate immune system in mice and changes the inflammatory reaction to a new stimulus.
METHODS: Following 3 d of TAC or sham-operation procedure (SOP), LPS (20 mg/kg) or PBS (control) were administered intraperitoneal for 10 min as well as for 6 h. Hemodynamic parameters were recorded to measure the effects of TAC and LPS. After TAC/SOP alone CD14 expression was monitored and after additional 6 h of LPS/PBS the expression of CD14, TLR4 and proinflammatory cytokines were determined by western-blot, ELISA and RNase protection assay, respectively. Following TAC/SOP and 10 min of LPS/PBS, NFkappaB activation was investigated by EMSA.
RESULTS: TAC induced cardiac hypertrophy and elevated blood pressure. LPS application led to hypotension and other symptoms of sepsis. CD14 expression increased after TAC alone and even further after additional LPS challenge. However, we did not detect changes of TLR4 expression. Also NFkappaB activation increased after LPS challenge higher in the TAC than in the SOP group. LPS-stimulation induced also higher cytokine expression in the TAC than in the SOP group.
CONCLUSION: TAC modulates innate immunity by regulating the expression of CD14 and changes the myocardial tissue to respond more powerful to LPS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699746     DOI: 10.1007/s00395-006-0597-0

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  6 in total

Review 1.  Toll-like receptors: new players in myocardial ischemia/reperfusion injury.

Authors:  Tuanzhu Ha; Li Liu; Jim Kelley; Race Kao; David Williams; Chuanfu Li
Journal:  Antioxid Redox Signal       Date:  2011-04-08       Impact factor: 8.401

2.  Tlr2 deficiency does not limit the development of left ventricular hypertrophy in a model of transverse aortic constriction induced pressure overload.

Authors:  Tippaporn Bualeong; Sied Kebir; Dorothea Hof; Lina Goelz; Mathias Graewe; Stefan Felix Ehrentraut; Pascal Knuefermann; Georg Baumgarten; Rainer Meyer; Heidi Ehrentraut
Journal:  J Negat Results Biomed       Date:  2016-04-25

3.  Soluble adenylyl cyclase: A novel player in cardiac hypertrophy induced by isoprenaline or pressure overload.

Authors:  Ilona Schirmer; Tippaporn Bualeong; Heidi Budde; Diana Cimiotti; Avinash Appukuttan; Nicole Klein; Philip Steinwascher; Peter Reusch; Andreas Mügge; Rainer Meyer; Yury Ladilov; Kornelia Jaquet
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

4.  Contractile deficits in engineered cardiac microtissues as a result of MYBPC3 deficiency and mechanical overload.

Authors:  Zhen Ma; Nathaniel Huebsch; Sangmo Koo; Mohammad A Mandegar; Brian Siemons; Steven Boggess; Bruce R Conklin; Costas P Grigoropoulos; Kevin E Healy
Journal:  Nat Biomed Eng       Date:  2018-09-10       Impact factor: 25.671

Review 5.  Key Player in Cardiac Hypertrophy, Emphasizing the Role of Toll-Like Receptor 4.

Authors:  Zheng Xiao; Bin Kong; Hongjie Yang; Chang Dai; Jin Fang; Tianyou Qin; He Huang
Journal:  Front Cardiovasc Med       Date:  2020-11-26

6.  Tlr4 Deficiency Protects against Cardiac Pressure Overload Induced Hyperinflammation.

Authors:  Heidi Ehrentraut; Stefan Felix Ehrentraut; Olaf Boehm; Sakina El Aissati; Fabian Foltz; Lina Goelz; David Goertz; Sied Kebir; Christina Weisheit; Michael Wolf; Rainer Meyer; Georg Baumgarten
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.